Moderna, Inc. vs Phillips 66 — how do they compare? Moderna, Inc. trades at $59.73 (market cap $23.60B), while Phillips 66 trades at $212.27 (market cap $83.72B). The key difference: Phillips 66 is far larger — about 3.5× Moderna, Inc.'s market cap, and Phillips 66 pays a 2.43% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | PSX | |
|---|---|---|
Market Cap | $23.60B | $83.72B |
Sector | Health | Energy |
52-Week High | $81.80 | $208.80 |
52-Week Low | $22.36 | $118.37 |
Enterprise Value | $19.70B | $105.69B |
Dividend Yield | — | 2.43% |
Trailing returns across standard periods
Latest headlines on both assets
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →